Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

  • Seok, Hyeri; 
  • Ko, Jae-Hoon; 
  • Peck, Kyong Ran; 
  • Kim, Ji-Yeon; 
  • Lee, Ji Hye; 
  • 외 5명
Citations

WEB OF SCIENCE

0

초록

BackgroundAlthough -lactam monotherapy may be sufficient in non-critically ill patients with community-acquired pneumonia, the value of combination antibiotic regimens in community-onset neutropenic pneumonia remains unclear.MethodsA retrospective cohort study was conducted to compare the effects of combination antibiotic regimens to those of -lactam monotherapy in cancer patients with community-onset neutropenic pneumonia. Electronic medical records of patients diagnosed with community-onset neutropenic pneumonia between March 1995 and February 2015 at a tertiary care center were reviewed.ResultsDuring the study period, 165 cancer patients with community-onset neutropenic pneumonia were identified. Seventy-two patients received -lactam monotherapy and 93 received combination therapy (-lactam plus either a macrolide or fluoroquinolone). Causative pathogens were identified in 27.9% of the patients, and only two were positive for atypical pathogens. Although 30-day mortality was higher in the -lactam group (15.3% versus 4.3%; P=0.015), combination therapy was not associated with a statistically significant survival benefit in the multivariate analysis (hazard ratio 0.85, 95% confidence interval 0.20-3.67; P=0.827). Duration of neutropenia, C-reactive protein level, and Multinational Association for Supportive Care in Cancer risk index were significant factors for 30-day mortality. In a subgroup analysis of patients treated with cefepime, the most frequently used -lactam (63.0%), combination therapy also showed no significant survival benefit.ConclusionsCombination antibiotic regimens were not associated with a survival benefit over -lactam monotherapy in the treatment of community-onset neutropenic pneumonia. Unnecessary combination therapy should be reconsidered in cancer patients who are at high risk for adverse drug reactions and colonization with multi-drug resistant organisms.

키워드

Cancer; Combination antibiotic regimens; Febrile neutropenia; Pneumonia; CHEMOTHERAPY-INDUCED NEUTROPENIA; INFECTIOUS-DISEASES-SOCIETY; ACQUIRED PNEUMONIA; ANTIMICROBIAL AGENTS; FEBRILE NEUTROPENIA; BETA-LACTAM; LOW-RISK; GUIDELINES; ERYTHROMYCIN; AZITHROMYCIN
제목
Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens
저자
Seok, Hyeri; Ko, Jae-Hoon; Peck, Kyong Ran; Kim, Ji-Yeon; Lee, Ji Hye; Park, Ga Eun; Cho, Sun Young; Kang, Cheol-In; Lee, Nam Yong; Chung, Doo Ryeon
DOI
10.1186/s41479-019-0061-1
발행일
2019-06
유형
Case Reports
저널명
Pneumonia
권
11